CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -4.45: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
858.76MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8680xvs all stocks
52-Week Change
-17.00%vs all stocks
Market Capitalization
858.76MUSDvs all stocks (USD)
Enterprise Value
701.46MUSDvs all stocks (USD)
Forward P/E
-8.87xvs Biotechnology peers
Price to Book (MRQ)
5.09xvs Biotechnology peers
Enterprise to EBITDA
-2.24xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-45.03%vs Biotechnology peers
Return on Equity (TTM)
-107.88%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-312.56MUSDvs all stocks (USD)
Net Income (TTM)
-313.94MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-280.34MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-172.25MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2026 · Mar 31, 2026Operating Income
-318.31MUSDvs all stocks (USD)
Pre-tax Income
-314.49MUSDFY2026 · Mar 31, 2026Income Tax Expense
-551.00KUSDFY2026 · Mar 31, 2026Net Income
-313.94MUSDFY2026 · Mar 31, 2026EBIT
-305.63MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
-315.93MUSDFY2026 · Mar 31, 2026Research & Development
221.18MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
98.73MUSDFY2026 · Mar 31, 2026Other Operating Expenses
-1.60MUSDFY2026 · Mar 31, 2026Non-operating Interest Expense
8.86MUSDFY2026 · Mar 31, 2026EPS (Basic)
-3.38USDFY2026 · Mar 31, 2026EPS (Diluted)
-3.38USDFY2026 · Mar 31, 2026Basic Shares Outstanding
92.80MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
92.80MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-313.94MUSDFY2026 · Mar 31, 2026Operating Cash Flow
-279.00MUSDFY2026 · Mar 31, 2026Free Cash Flow
-283.22MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
210.73MUSDFY2026 · Mar 31, 2026Income Tax Paid
5.00KUSDFY2026 · Mar 31, 2026Interest Paid
4.69MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-313.94MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
3.33MUSDFY2026 · Mar 31, 2026Stock-based Compensation
32.27MUSDFY2026 · Mar 31, 2026Other Non-cash Items
5.13MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
451.00KUSDFY2026 · Mar 31, 2026Change in Accounts Payable (CF)
-4.94MUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.30MUSDFY2026 · Mar 31, 2026Capital Expenditures
-4.22MUSDFY2026 · Mar 31, 2026Purchase of Investments
-77.89MUSDFY2026 · Mar 31, 2026Sale of Investments
392.96MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
310.84MUSDFY2026 · Mar 31, 2026Long-term Debt Issuance
35.00MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-736.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
65.41MUSDFY2026 · Mar 31, 2026Shares Outstanding
82.72MSharesUpdated Jul 19, 2026Float Shares
59.71MSharesUpdated Jul 19, 2026Shares Short
23.67MSharesUpdated Jul 19, 2026Short Ratio
5.48daysvs all stocks
Short % of Shares Outstanding
49.88%vs all stocks
% Held by Insiders
2.56%vs all stocks
% Held by Institutions
95.37%vs all stocks
Total Cash (MRQ)
268.89MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.20USDUpdated Jul 19, 2026Total Debt (MRQ)
111.59MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6716xvs Biotechnology peers
Current Ratio (MRQ)
4.79xvs Biotechnology peers
Book Value per Share (MRQ)
2.01USDUpdated Jul 19, 2026Total Assets
332.39MUSDvs all stocks (USD)
Total Current Assets
279.12MUSDFY2026 · Mar 31, 2026Total Liabilities
166.23MUSDFY2026 · Mar 31, 2026Total Non-current Assets
53.27MUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
108.00MUSDFY2026 · Mar 31, 2026Total Current Liabilities
58.23MUSDFY2026 · Mar 31, 2026Cash
88.72MUSDFY2026 · Mar 31, 2026Cash Equivalents
120.30MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
209.02MUSDFY2026 · Mar 31, 2026Other Short-term Investments
59.87MUSDFY2026 · Mar 31, 2026Accounts Payable
6.67MUSDFY2026 · Mar 31, 2026Short-term Debt
4.04MUSDFY2026 · Mar 31, 2026Other Current Liabilities
2.76MUSDFY2026 · Mar 31, 2026Long-term Debt
107.55MUSDFY2026 · Mar 31, 2026Other Non-current Liabilities
455.00KUSDFY2026 · Mar 31, 2026Common Stock (Book)
82.00KUSDFY2026 · Mar 31, 2026Retained Earnings
-1.26BUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
166.16MUSDvs all stocks (USD)
52-Week Low
1.50USDUpdated Jul 19, 202652-Week High
13.24USDUpdated Jul 19, 202652-Week Change
-17.00%vs all stocks
Beta
0.8680xvs all stocks
50-Day MA
8.22USDUpdated Jul 19, 2026200-Day MA
7.58USDUpdated Jul 19, 2026Avg 10-Day Volume
2.70MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.24MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.38USDUpdated Jul 19, 2026Other Income / Expense
12.68MUSDFY2026 · Mar 31, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.79Altman Z-Score: -4.45
Financial Health
Altman Z-Score -4.45: distress zoneCritical
Altman Z-Score: -4.45
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk